B
Bullisch
Bullisch · 25%CMMB
$1.23
Szenariopreis
$1.380
+0.143 (+10.39%)Zum Schluss
Loading chart…
- Hoch
- 1.380
- Eröffnung
- 1.270
- Volumengewichteter Durchschnittskurs
- 1.34
- Volumen
- 59.32K
- Marktkap.
- 13.81M
- Tief
- 1.250
- Umsatz
- 79.28K
- EV/EBITDA, TTM
- 0.00
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
KI-Analyse of Chemomab Therapeutics Ltd (CMMB)
KaufenChemomab Therapeutics Ltd. (CMMB) appears to be a good buy right now, trading at $1.38, which is significantly below its 52-week high of $2.99, indicating potential upside. The stock has shown a strong 5-day change of +18.96%, suggesting positive momentum. However, the company has a negative net income with losses reaching -2,165,000 USD in Q2 2026, which presents a risk to consider.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Chemomab Therapeutics Ltd (CMMB) beträgt 12.94, verglichen mit dem 5-Jahres-Durchschnitt von -15.29.
Alphio-AI-Kursszenarien für CMMB
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
8.508-19NewsfilterChemomab and Scipher Merger Progressing
7.507-10NASDAQ.COMKey Developments in Biotech Sector This Week
8.507-08seekingalphaChemomab and Scipher Enter Definitive Merger Agreement
- 8.507-08Newsfilter
Chemomab and Scipher Merge to Advance RA Drug Development
2.007-03NASDAQ.COMBiotech Companies See Significant Stock Gains
CMMB FAQ – beantwortet von Alphio AI
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Chemomab Therapeutics Ltd. (CMMB) appears to be a good buy right now, trading at $1.38, which is significantly below its 52-week high of $2.99, indicating potential upside. The stock has shown a strong 5-day change of +18.96%, suggesting positive momentum. However, the company has a negative net income with losses reaching -2,165,000 USD in Q2 2026, which presents a risk to consider.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.